Follicum

Follicum
About Us
Change country

Follow us:
Share:
Subscribe:

About Us

Follicum AB (Spotlight: FOLLI) develops drugs based on tissue repair peptides with potential use in a range of diseaseareas. The company's most advanced drug candidate, FOL-005, is administered using a unique formulation technology found safe and well-tolerated in a comprehensive Phase II study conducted in collaboration with internationally renowned specialist clinics. In the field of diabetes, a project is being conducted that aims to protect insulin-producing cells from damage, thus reducing the risk for complications. The projects have the potential to become so-called first-in-class medicines. For more information, visit www.follicum.com.

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Follicum will present FOL-005 at the scientific conference European Hair Research Society, 18-20 May 2018

Wed, May 16, 2018 08:18 CET

Follicum AB (“Follicum” or “the Company”) today announces that CEO Jan Alenfall will give a presentation of the development of FOL-005 at the conference European Hair Research Society, which takes place in Bologna, Italy, 18-20 May 2018.The presentation will be included in the part of the conference that will discuss cell-based, growth-factor-based and pharmaceutical treatments. Follicum will also present a poster with the title “FOL-005 – a novel peptide drug regulates hair growth in a Phase I/IIa study” at the same conference. Information about the poster and the scientific program:

There are no items matching the current filter

There are no more items matching the current filter

Back to top

Share

About Us

Follicum will present FOL-005 at the scientific conference European Hair Research Society, 18-20 May 2018